NCT05775380View on ClinicalTrials.gov

The Role of Pioglitazone in Vascular Transcriptional Remodeling

PHASE4RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

June 15, 2023

Primary Completion Date

June 28, 2024

Study Completion Date

December 22, 2024

Conditions
Myocardial Reperfusion Injury
Interventions
DRUG

Pioglitazone 45 mg

We investigated the role of pioglitazone hydrochloride 45mg/day for five days in patients admitted for coronary artery bypass grafting (CABG) in order to investigate vascular SPhk1 expression, vascular transcriptome and proteome remodeling, as well as S1P content in HDL

Trial Locations (1)

13083-887

RECRUITING

University of Campinas, Campinas

All Listed Sponsors
lead

University of Campinas, Brazil

OTHER